New Zealand markets close in 18 minutes

Boston Scientific Corporation (BSX)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
42.97-0.48 (-1.10%)
At close: 04:00PM EST
42.31 -0.66 (-1.54%)
After hours: 07:49PM EST
Full screen
Trade prices are not sourced from all markets
Previous close43.45
Bid42.31 x 1100
Ask42.93 x 800
Day's range42.69 - 43.54
52-week range35.05 - 46.29
Avg. volume8,240,611
Market cap61.232B
Beta (5Y monthly)0.88
PE ratio (TTM)55.88
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    BOSTON SCIENTIFIC INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Boston Scientific Corporation - BSX

    Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Boston Scientific Corporation (NYSE: BSX).

  • Business Wire

    DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Boston Scientific Corporation and Encourages Investors with Losses of $100,000 to Contact the Firm

    DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Boston Scientific Corporation

  • GlobeNewswire

    BSX Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Boston Scientific Corporation Shareholders of Class Action and Lead Plaintiff Deadline: February 3, 2021

    NEW YORK, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Boston Scientific Corporation ("Boston Scientific" or the "Company") (NASDAQ: BSX) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Boston Scientific securities between April 24, 2019 to November 16, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site: This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the LOTUS Edge Aortic Valve System's product delivery system was dysfunctional and threatened the continued viability of the entire product line; (2) as a result, the Company had materially overstated the continued commercial viability and profitability of the LOTUS Edge Aortic Valve System; and (3) as a result, the Company's public statements were materially false and misleading at all relevant times. A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Boston Scientific you have until February 3, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes. Contact:Bronstein, Gewirtz & Grossman, LLCPeretz Bronstein or Yael Hurwitz 212-697-6484 |